Study #2024-1337
A randomized Phase 2 trial of Nivolumab, Relatlimab plus Ipilimumab vs. Nivolumab plus Ipilimumab in first-line advanced renal cell carcinoma (RCC)
MD Anderson Study Status
Enrolling
Treatment Agent
Drugs Nivolumab, Ipilimumab, BMS-986213 (Relatlimab-Nivolumab FDC)
Description
This is a phase 2 stratified, randomized, multicenter, study investigating the efficacy of a triplet arm treating with nivolumab 480 mg every 4 weeks (Q4W), relatlimab 160 mg Q4W and ipilimumab 1 mg/kg every 8 weeks (Q8W) intravenous (IV) versus a doublet arm treating with nivolumab 480 mg Q3W and ipilimumab 1mg/kg Q3W IV in first-line advanced RCC.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Renal Cell Carcinoma, Clear Cell
Study phase:
Phase II
Physician name:
Eric Jonasch
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-855-581-8877
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.